Nautilus Biotechnology Inc (NAUT)

$2.92

-0.01

(-0.34%)

Market is closed - opens 8 PM, 06 Dec 2023

Performance

  • $2.77
    $2.94
    $2.92
    downward going graph

    5.14%

    Downside

    Day's Volatility :5.78%

    Upside

    0.68%

    downward going graph
  • $1.50
    $4.65
    $2.92
    downward going graph

    48.63%

    Downside

    52 Weeks Volatility :67.74%

    Upside

    37.2%

    downward going graph

Returns

PeriodNautilus Biotechnology Inc
3 Months
-7.3%
6 Months
-2.01%
1 Year
70.76%
3 Years
-71.09%

Highlights

Market Capitalization
366.2M
Book Value
$2.22
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-0.47
Wall Street Target Price
5.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-13.37%
Return On Equity TTM
-19.93%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-70.8M
Diluted Eps TTM
-0.47
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.56
EPS Estimate Next Year
-0.73
EPS Estimate Current Quarter
-0.17
EPS Estimate Next Quarter
-0.19

Analyst Recommendation

Buy
    70%Buy
    30%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Nautilus Biotechnology Inc(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
3
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 71.23%

Current $2.92
Target $5.00

Technicals Summary

Sell

Neutral

Buy

Nautilus Biotechnology Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Nautilus Biotechnology Inc
Nautilus Biotechnology Inc
19.18%
-2.01%
70.76%
-71.09%
-71.09%
Moderna, Inc.
Moderna, Inc.
8.62%
-38.31%
-54.89%
-50.93%
320.86%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-1.38%
9.73%
9.82%
65.7%
115.07%
Novo Nordisk A/s
Novo Nordisk A/s
-1.43%
23.95%
58.41%
192.13%
336.59%
Seagen, Inc.
Seagen, Inc.
0.74%
10.42%
83.05%
20.41%
247.89%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-8.19%
7.19%
13.58%
55.97%
97.18%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Nautilus Biotechnology Inc
Nautilus Biotechnology Inc
NA
NA
NA
-0.56
-0.2
-0.13
0.0
2.22
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-12.72
-0.22
-0.07
0.0
35.32
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
23.18
23.18
1.75
42.5
0.17
0.09
0.01
234.47
Novo Nordisk A/s
Novo Nordisk A/s
41.18
41.18
4.02
2.67
0.89
0.22
0.01
20.77
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-4.16
-0.28
-0.13
0.03
13.52
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.38
26.38
0.5
15.04
0.23
0.14
0.0
64.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Nautilus Biotechnology Inc
Nautilus Biotechnology Inc
Buy
$366.2M
-71.09%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$30.4B
320.86%
24.73
-38.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$88.5B
115.07%
23.18
30.47%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$459.0B
336.59%
41.18
35.11%
Seagen, Inc.
Seagen, Inc.
Hold
$40.2B
247.89%
NA
-32.61%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$90.5B
97.18%
26.38
35.94%

Institutional Holdings

  • Perceptive Advisors LLC

    7.29%
  • Cercano Management LLC

    5.74%
  • Madrona Venture Group, LLC

    4.82%
  • BlackRock Inc

    2.99%
  • Vanguard Group Inc

    2.25%
  • Comprehensive Financial Management LLC

    1.77%

Corporate Announcements

  • Nautilus Biotechnology Inc Earnings

    Nautilus Biotechnology Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

born from the founders’ recognition that their diverse but complementary skills and experiences would enable them to successfully address challenges that others had not, the company set about solving a vexing problem: how to bring true proteomics to the world in a way that accelerates therapeutic development, dramatically improves medical diagnostics, and makes personalized and predictive medicine a reality. the extraordinary team at nautilus represents a wide spectrum of disciplines and expertise, including: protein chemists, chip designers, molecular biologists, data scientists, material scientists, biophysicists, optical engineers, microfluidics engineers, bioinformaticists, software engineers, and more. nautilus is positioned to revolutionize proteomics, transform the way drugs are developed, and significantly improve the way human health is managed.

Organization
Nautilus Biotechnology Inc
Employees
160
CEO
Mr. Sujal M. Patel
Industry
Healthcare

FAQs